Drug intelligence / Profile preview

P.Happi

Development stage: Unknown
Lead developer: B.Y.M. Technologies
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Topical

Overview

P.Happi is a daily intimate serum containing B.Y.M. 1405, a live predatory bacterium (*Bdellovibrio bacteriovorus*). It represents a novel live biotherapeutic modality designed to support the female intimate microbiome by selectively targeting and reducing harmful Gram-negative bacteria, such as *Escherichia coli*, which are common causes of urinary tract infections (UTIs) and irritation. Unlike traditional antibiotics, this predatory bacterium preys specifically on Gram-negative pathogens while preserving beneficial *Lactobacilli*. The serum is applied topically to the external intimate area (vulva, labia, and perineum) to provide moisturizing care and maintain microbial balance during periods of hormonal shifts, stress, or after sexual activity. As of March 2024, the product is commercially available in the UK market.

Brand names: P.Happi
Other names: Bdellovibrio bacteriovorus

Beyond the preview

Go deeper on P.Happi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P.Happi.

Explore the full profile